Monopar Enrolls First Patient in Phase 1 Trial for MNPR-101-Zr

Monopar Therapeutics Inc., a clinical-stage company specializing in radiopharmaceuticals, has initiated the enrollment for its first-in-human Phase 1 clinical trial of the innovative imaging agent MNPR-101-Zr. This development marks a significant milestone in the company's efforts to advance cancer treatment. The trial aims to evaluate the safety and dosimetry of MNPR-101-Zr in up to 12 patients who are battling advanced cancers. MNPR-101-Zr is a novel radiopharmaceutical that combines Monopar's proprietary antibody, MNPR-101, with the radioisotope zirconium-89. This combination targets the urokinase plasminogen activator receptor (uPAR), which is implicated in some of the most aggressive forms of cancer.

The clinical trial is being conducted under the leadership of Professor Rodney Hicks, a distinguished nuclear medicine physician at the Melbourne Theranostic Innovation Centre. This study represents the first human trial of a radiolabeled monoclonal antibody targeting uPAR, a protein receptor found in several deadly cancers, including pancreatic, triple negative breast, and colorectal cancers.

Chandler Robinson, MD, Chief Executive Officer of Monopar, expressed optimism about the trial, emphasizing the critical importance of uPAR as a cancer target. "uPAR is a well-credentialed cancer target found in some of the most aggressive, deadly cancers. We are very much looking forward to seeing the biodistribution and dosimetry data from this study," he said.

Andrew Cittadine, the Chief Operating Officer of Monopar, echoed this sentiment, highlighting the potential impact of the trial on cancer treatment. "We are pleased to enroll our inaugural patient. Encouraging preclinical results in several challenging cancers underscore the potential of uPAR as a promising target to battle some of the most lethal cancers," Cittadine remarked.

Monopar Therapeutics Inc. is dedicated to developing pioneering treatments for cancer. The company's focus includes the Phase 1-stage MNPR-101-Zr for imaging advanced cancers, as well as the late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for treating advanced cancers. Additionally, Monopar is involved in early development programs targeting solid tumors.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!